- Five-Year Update to be Presented from
ADCETRIS Phase 3 ECHELON-1 and ECHELON-2 Clinical Trials -
- Additional Data Analyses Highlight Activities
Across Broad ADCETRIS Development Program -
Seagen Inc. (Nasdaq:SGEN) today announced multiple ADCETRIS®
(brentuximab vedotin) data presentations at the upcoming 62nd
American Society of Hematology (ASH) Annual Meeting and Exposition,
taking place virtually December 5-8, 2020. Data presentations will
include five-year updates from the phase 3 ECHELON-1 and ECHELON-2
clinical trials evaluating ADCETRIS plus a chemotherapy combination
regimen in frontline advanced stage Hodgkin lymphoma (HL) or
frontline peripheral T-cell lymphoma (PTCL). ADCETRIS is an
antibody-drug conjugate (ADC) directed to CD30, a defining marker
of classical HL and expressed on the surface of several types of
PTCL. ADCETRIS is being evaluated globally in more than 70
corporate- and investigator-sponsored clinical trials across
multiple settings in lymphoma and other indications.
“At this year’s ASH meeting, ADCETRIS will be featured in 18
data presentations, including five-year analyses from the ECHELON-1
and ECHELON-2 phase 3 frontline trials,” said Roger Dansey, M.D.,
Chief Medical Officer at Seagen. “Reaching five-years without
disease recurrence represents a significant clinical milestone for
patients, as they may be considered disease-free at this time
point. The five-year data presentations from our phase 3 ECHELON-1
and ECHELON-2 trials demonstrate ADCETRIS plus chemotherapy
resulted in superior clinical activity and durable benefit when
compared to outcomes with a standard chemotherapy regimen. We will
also present additional analyses from trials evaluating ADCETRIS in
combination with other therapies, with the goal of identifying
potential new treatment strategies that improve outcomes for
patients.”
Details of Seagen Presentations at
ASH:
Abstract Title
Abstract #
Presentation
Type / Date
Presenter
Company-Sponsored
Trials
Frontline Brentuximab Vedotin as
Monotherapy or in Combination for Older Hodgkin Lymphoma
Patients
#471
Oral presentation / Sunday, Dec. 6 at 2:15
p.m. PT
C. Yasenchak
Brentuximab Vedotin with Chemotherapy for
Patients with Previously Untreated, Stage III/IV Classical Hodgkin
lymphoma: 5-year Update of the ECHELON-1 Study
#2973
Poster presentation / Monday, Dec. 7, 7:00
a.m. - 3:30 p.m. PT
D. Straus
The ECHELON-2 Trial: 5-Year Results of a
Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and
CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with
CD30-positive Peripheral T-cell Lymphoma
#1150
Poster presentation / Saturday, Dec. 5,
7:00 a.m. - 3:30 p.m. PT
S. Horwitz
Economic Assessment of Diagnostic Revision
in Peripheral T-cell Lymphoma
#1606
Poster presentation / Saturday, Dec. 5,
7:00 a.m. - 3:30 p.m. PT
N. Liu
Nivolumab Combined with Brentuximab
Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma:
Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436
Study
#2045
Poster presentation / Sunday, Dec. 6, 7:00
a.m. - 3:30 p.m. PT
A. Santoro
Real-World Characteristics of Patients
with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab
Vedotin with Chemotherapy: A Retrospective Analysis with Propensity
Score Matching
#2499
Poster presentation / Sunday, Dec. 6, 7:00
a.m. - 3:30 p.m. PT
T. Phillips
Real-World Adherence to National
Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage
of PET/CT and Reported Deauville Scores in Advanced Stage Classical
Hodgkin Lymphoma: A Community Oncology Practice Perspective
#2033
Poster presentation / Sunday, Dec. 6, 7:00
a.m. - 3:30 p.m. PT
C. Yasenchak
SGN-CD30C, an Investigational
CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows
Strong Anti Tumor Activity and Superior Tolerability in Preclinical
Studies
#2089
Poster presentation / Sunday, Dec. 6, 7:00
a.m. - 3:30 p.m. PT
M. Ryan
Real-World Characteristics of Patients
with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab
Vedotin with Chemotherapy: A Retrospective Analysis with Propensity
Score Matching
#3418
Poster presentation / Monday, Dec. 7, 7:00
a.m. - 3:30 p.m. PT
J. Burke
Nodal Peripheral T-Cell Lymphoma with T
Follicular-Helper Phenotype: A Different Entity? Results of the
Spanish Retrospective Real-T Study
#2972
Poster presentation / Monday, Dec. 7, 7:00
a.m. - 3:30 p.m. PT
AM. Garcia-Sancho
Results from the International,
Multi-Center, Retrospective B-Holistic Study: Describing Treatment
Pathways and Outcomes for Classical Hodgkin Lymphoma
#2979
Poster presentation / Monday, Dec. 7, 7:00
a.m. - 3:30 p.m. PT
B. Ferhanoglu
Investigator-Sponsored
Trials
Increased Tumor Specific Cytotoxic T Cell
Responses and Reversion to a Favorable Cytokine Profile after
Treatment in Patients with Newly Diagnosed High Risk Hodgkin
Lymphoma Treated on Children’s Oncology Group Trial- AHOD1331
#595
Oral presentation / Monday, Dec. 7 at 9:15
a.m. PT
H. Dave
Addition of Brentuximab Vedotin to
Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a
LYSA Multicenter, Phase II Study. “The TOTAL Trial”
#1161
Poster presentation / Saturday, Dec. 5,
7:00 a.m. - 3:30 p.m. PT
O. Tournilhac
A Pilot Study of Brentuximab Vedotin,
Rituximab and Dose Attenuated CHP in Patients 75 Years and Older
with Diffuse Large B-Cell Lymphoma
#2102
Poster presentation / Sunday, Dec. 6, 7:00
a.m. - 3:30 p.m. PT
P. Reagan
Dose-Dense Brentuximab Vedotin Plus
Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for
Second Line Treatment in Relapsed/Refractory Classical Hodgkin
Lymphoma: Final Results of a Phase I/II Study
#2964
Poster presentation / Monday, Dec. 7, 7:00
a.m. - 3:30 p.m. PT
R. Lynch
A Phase I Trial Assessing the Feasibility
of Romidepsin Combined with Brentuximab Vedotin for Patients
Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma
#2970
Poster presentation / Monday, Dec. 7, 7:00
a.m. - 3:30 p.m. PT
S. Barta
Trials-in-Progress
Trial-in-Progress: Brentuximab Vedotin in
Combination with Lenalidomide and Rituximab in Subjects with
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
#2112
Poster presentation / Sunday, Dec. 6, 7:00
a.m. - 3:30 p.m. PT
N. Bartlett
A Phase 1 Study of Sea-CD70 in Myeloid
Malignancies
#2874
Poster presentation / Monday, Dec. 7, 7:00
a.m. - 3:30 p.m. PT
A. Aribi
Trial-in-Progress: Frontline Brentuximab
Vedotin and CHP (A+CHP) in Patients with Peripheral T-Cell Lymphoma
with Less Than 10% CD30 Expression
#2976
Poster presentation / Monday, Dec. 7, 7:00
a.m. - 3:30 p.m. PT
D. Jagadeesh
About Seagen
Seagen is a global biotechnology company that discovers,
develops and commercializes transformative cancer medicines to make
a meaningful difference in people’s lives. Seagen is headquartered
in the Seattle, Washington area, and has locations in California,
Canada, Switzerland and the European Union. For more information on
the company’s marketed products and robust pipeline, visit
www.seagen.com and follow @SeagenGlobal on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the therapeutic
potential of ADCETRIS plus chemotherapy combination regimens in
frontline advanced stage Hodgkin lymphoma (HL) and frontline
peripheral T-cell lymphoma (PTCL), and in other indications. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements due to factors such
as unexpected adverse events, adverse regulatory actions, the
degree of utilization and adoption of an approved treatment regimen
by prescribing physicians, the difficulty and uncertainty of
pharmaceutical product development, negative or disappointing
clinical trial results and risks related to the duration and
severity of the COVID-19 pandemic. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the difficulty and uncertainty of pharmaceutical
product development, the risk of adverse events or safety signals,
the inability to show sufficient activity in clinical trials and
the possibility of adverse regulatory actions. More information
about the risks and uncertainties faced by Seagen is contained
under the caption “Risk Factors” included in the Company’s
Quarterly Report on Form 10-Q for the quarter ended September 30,
2020 filed with the Securities and Exchange Commission. Seagen
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201105005329/en/
Media: Monique Greer (425) 527-4641 mgreer@seagen.com
Investors: Peggy Pinkston (425) 527-4160
ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From May 2023 to May 2024